UA96279C2 - Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo - Google Patents
Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogoInfo
- Publication number
- UA96279C2 UA96279C2 UAA200807663A UAA200807663A UA96279C2 UA 96279 C2 UA96279 C2 UA 96279C2 UA A200807663 A UAA200807663 A UA A200807663A UA A200807663 A UAA200807663 A UA A200807663A UA 96279 C2 UA96279 C2 UA 96279C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- fragment
- binding
- isolated antibody
- human nogo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к изолированному антителу или его фрагменту, способному к связыванию с человеческим NOGO, нуклеиновой кислоты, которая его кодирует, вектора, клетки-хозяина, способа получения данного антитела. Изобретение также относится к фармацевтической композиции, которая содержит антитело, и применение данного антитела для приготовления лекарственного средства для лечения или профилактики инсульта и других неврологических заболеваний.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0525662.3A GB0525662D0 (en) | 2005-12-16 | 2005-12-16 | Immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
UA96279C2 true UA96279C2 (ru) | 2011-10-25 |
Family
ID=35736284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200807663A UA96279C2 (ru) | 2005-12-16 | 2006-12-14 | Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo |
Country Status (31)
Country | Link |
---|---|
US (2) | US8362208B2 (ru) |
EP (2) | EP1960429B1 (ru) |
JP (1) | JP5015949B2 (ru) |
KR (1) | KR101355118B1 (ru) |
CN (1) | CN101374863B (ru) |
AR (1) | AR057239A1 (ru) |
AU (1) | AU2006325228B2 (ru) |
BR (1) | BRPI0619855A2 (ru) |
CA (1) | CA2633501C (ru) |
CR (1) | CR10099A (ru) |
CY (1) | CY1113094T1 (ru) |
DK (1) | DK1960429T3 (ru) |
EA (1) | EA015536B1 (ru) |
ES (1) | ES2389380T3 (ru) |
GB (1) | GB0525662D0 (ru) |
HK (1) | HK1119720A1 (ru) |
HR (1) | HRP20120684T1 (ru) |
IL (1) | IL192086A0 (ru) |
JO (1) | JO2795B1 (ru) |
MA (1) | MA30041B1 (ru) |
MY (1) | MY149492A (ru) |
NO (1) | NO20082699L (ru) |
NZ (1) | NZ569143A (ru) |
PE (1) | PE20071099A1 (ru) |
PL (1) | PL1960429T3 (ru) |
PT (1) | PT1960429E (ru) |
SI (1) | SI1960429T1 (ru) |
TW (1) | TWI378940B (ru) |
UA (1) | UA96279C2 (ru) |
WO (1) | WO2007068750A2 (ru) |
ZA (2) | ZA200805111B (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY149546A (en) * | 2007-11-02 | 2013-09-13 | Novartis Ag | Improved nogo-a binding molecules and pharmaceutical use tereof |
CN106349390B (zh) | 2008-04-02 | 2019-12-10 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
KR20110010758A (ko) | 2008-05-06 | 2011-02-07 | 글락소 그룹 리미티드 | 생물학적 활성제의 캡슐화 |
CA2730473A1 (en) * | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
IN2014KN02952A (ru) | 2012-07-05 | 2015-05-08 | Glaxo Group Ltd | |
US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
US11013815B2 (en) | 2017-06-14 | 2021-05-25 | Monojul, Llc | High-affinity anti-human folate receptor beta antibodies and methods of use |
CN114599676A (zh) | 2019-10-24 | 2022-06-07 | 诺华康制药股份公司 | 新型抗-Nogo-A抗体 |
GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
KR20240021959A (ko) | 2021-06-17 | 2024-02-19 | 펫메딕스 리미티드 | 항개 cd20 항체 |
WO2023067358A1 (en) | 2021-10-21 | 2023-04-27 | Petmedix Ltd | Proteins comprising the extracellular domain of p75ntr |
CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
WO2023152486A1 (en) | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Therapeutic antibodies |
WO2024041450A1 (zh) * | 2022-08-22 | 2024-02-29 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
GB202217993D0 (en) | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Therapeutic antibodies |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5250414A (en) | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU668423B2 (en) | 1992-08-17 | 1996-05-02 | Genentech Inc. | Bispecific immunoadhesins |
GB9403250D0 (en) | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
ES2227769T3 (es) | 1994-05-27 | 2005-04-01 | Glaxosmithkline S.P.A. | Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina. |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
EP0835127B1 (en) | 1995-06-27 | 2004-09-08 | Research Foundation of Cuny, Hunter College | Composition containing a myelin-associated glycoprotein (mag) inhibitor which comprises an altered or mutated form of mag |
US6420338B1 (en) * | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
EP2264174A3 (en) | 1998-07-22 | 2012-03-07 | SmithKline Beecham Limited | Protein similar to neuroendocrine-specific protein, and encoding CDNA |
CN1721444A (zh) | 1998-11-06 | 2006-01-18 | 苏黎世大学 | Nogo基因的核苷酸序列和蛋白序列以及基于其的方法 |
FR2792199B3 (fr) | 1999-04-13 | 2001-05-18 | Sanofi Sa | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
GB0318727D0 (en) | 2003-08-08 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
DE10338136A1 (de) | 2003-08-15 | 2005-03-24 | European Molecular Biology Laboratory | Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge |
GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
JP4901480B2 (ja) * | 2003-12-22 | 2012-03-21 | グラクソ グループ リミテッド | 神経疾患治療用の、nogo−aを中和する免疫グロブリン |
EP1761561B1 (en) * | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
EP1786463A4 (en) * | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | ANTIBODY AGAINST NOGO RECEPTOR |
-
2005
- 2005-12-16 GB GBGB0525662.3A patent/GB0525662D0/en not_active Ceased
-
2006
- 2006-12-14 KR KR1020087017348A patent/KR101355118B1/ko not_active IP Right Cessation
- 2006-12-14 NZ NZ569143A patent/NZ569143A/en not_active IP Right Cessation
- 2006-12-14 UA UAA200807663A patent/UA96279C2/ru unknown
- 2006-12-14 AU AU2006325228A patent/AU2006325228B2/en not_active Ceased
- 2006-12-14 MY MYPI20082130A patent/MY149492A/en unknown
- 2006-12-14 CN CN2006800529521A patent/CN101374863B/zh not_active Expired - Fee Related
- 2006-12-14 WO PCT/EP2006/069737 patent/WO2007068750A2/en active Application Filing
- 2006-12-14 EP EP06830633A patent/EP1960429B1/en active Active
- 2006-12-14 TW TW095146890A patent/TWI378940B/zh not_active IP Right Cessation
- 2006-12-14 PT PT06830633T patent/PT1960429E/pt unknown
- 2006-12-14 EA EA200801343A patent/EA015536B1/ru not_active IP Right Cessation
- 2006-12-14 PE PE2006001607A patent/PE20071099A1/es not_active Application Discontinuation
- 2006-12-14 DK DK06830633.1T patent/DK1960429T3/da active
- 2006-12-14 EP EP20100162457 patent/EP2228391A3/en not_active Withdrawn
- 2006-12-14 ES ES06830633T patent/ES2389380T3/es active Active
- 2006-12-14 SI SI200631393T patent/SI1960429T1/sl unknown
- 2006-12-14 BR BRPI0619855-4A patent/BRPI0619855A2/pt not_active IP Right Cessation
- 2006-12-14 AR ARP060105524A patent/AR057239A1/es active IP Right Grant
- 2006-12-14 US US12/097,279 patent/US8362208B2/en not_active Expired - Fee Related
- 2006-12-14 JP JP2008545009A patent/JP5015949B2/ja not_active Expired - Fee Related
- 2006-12-14 PL PL06830633T patent/PL1960429T3/pl unknown
- 2006-12-14 CA CA2633501A patent/CA2633501C/en not_active Expired - Fee Related
- 2006-12-24 JO JO2006457A patent/JO2795B1/en active
-
2008
- 2008-06-11 MA MA31018A patent/MA30041B1/fr unknown
- 2008-06-11 NO NO20082699A patent/NO20082699L/no not_active Application Discontinuation
- 2008-06-11 ZA ZA200805111A patent/ZA200805111B/xx unknown
- 2008-06-12 IL IL192086A patent/IL192086A0/en not_active IP Right Cessation
- 2008-06-20 CR CR10099A patent/CR10099A/es unknown
- 2008-12-08 HK HK08113307.3A patent/HK1119720A1/xx not_active IP Right Cessation
-
2009
- 2009-09-04 ZA ZA200906162A patent/ZA200906162B/en unknown
-
2012
- 2012-08-29 HR HRP20120684TT patent/HRP20120684T1/hr unknown
- 2012-09-05 CY CY20121100801T patent/CY1113094T1/el unknown
-
2013
- 2013-01-28 US US13/751,588 patent/US20130287781A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA96279C2 (ru) | Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo | |
MX2010003574A (es) | Anticuerpos il-23. | |
WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
WO2007104529A3 (en) | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
UA90048C2 (ru) | Кондиционированная композиция и способ ее получения | |
WO2006029176A3 (en) | Cancer-testis antigens | |
MX2007003013A (es) | Amidas biciclicas como inhibidores de cinasa. | |
MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
WO2010066684A3 (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
WO2005019258A3 (en) | Compositions and methods for the treatment of immune related diseases | |
MX2009003093A (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
WO2010021874A3 (en) | Engineered anti-il-13 antibodies, compositions, methods and uses | |
DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
WO2006081826A3 (en) | Survivin peptide vaccine | |
JO2576B1 (en) | Antibodies | |
UA96141C2 (ru) | Нейтрализующее антитело, которое имеет специфичность к человеческому il-6 | |
UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
TW200716646A (en) | (S)-N-methylnaltrexone | |
MX2008009886A (es) | Anticuerpos que enlazan par-2. | |
TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
IL171914A0 (en) | Variants of il-18bp, their preparation and pharmaceutical compositions containing them | |
WO2011038933A3 (en) | Anti-hsv antibody | |
WO2008136848A3 (en) | Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease | |
UA99716C2 (ru) | Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra) | |
WO2010129048A3 (en) | Therapeutic compounds |